智能手机通话语音生物标志物追踪REM睡眠行为障碍与帕金森病进展
这项24个月纵向研究纳入孤立性快速眼动睡眠行为障碍(iRBD)、早期帕金森病(PD)及匹配健康对照,通过标准化手机应用在通话中连续采集语音并分析声学特征。从71名参与者收集超过31,000次通话(>1,000小时),发现iRBD和PD组基于频谱变化及人工智能神经嵌入的语音损害严重程度终点均显著下降,iRBD组还出现元音发音和发音速率下降。基于神经嵌入终点的时效分析估计,2年神经保护试验(目标50%药效)每臂需74例iRBD和84例PD参与者。
要点
- 手机通话语音分析无需患者努力或临床监督,可检测前驱期和早期突触核蛋白病的语音衰退。
- iRBD和PD组基于频谱变化及AI神经嵌入的语音损害严重程度终点较对照显著下降。
- iRBD组还出现元音发音和发音速率下降。
核心结论
- 手机通话语音分析可被动检测前驱期和早期突触核蛋白病中的语音衰退,可能为临床试验设计和神经保护干预终点提供范式转变。
研究设计与样本
- 24个月纵向研究,纳入孤立性REM睡眠行为障碍(iRBD)、早期帕金森病(PD)及匹配健康对照,在基线、1年和2年进行临床评估。
- 通过标准化智能手机应用在通话中连续采集语音,分割并分析语音损害严重程度终点及单音调、元音发音、音质和发音速率等关键声学特征。
- 采用线性混合效应模型估计语音进展,并计算在预期治疗效果下证明进展减缓所需的样本量。
主要发现
- 从71名参与者收集超过31,000次通话(>1,000小时),包括iRBD、PD和健康对照。
- 与对照相比,iRBD和PD个体的基于频谱变化和人工智能神经嵌入的语音损害严重程度终点均显著下降。
- iRBD受试者还表现出元音发音和发音速率下降。
关键数值与推荐
- 对于2年神经保护试验 aiming for 50% drug efficacy,基于神经嵌入终点的时效分析最有效样本量估计为每臂74例iRBD和84例PD参与者。
临床怎么用
- 手机通话语音分析无需患者努力或临床监督,可作为前驱期和早期突触核蛋白病语音衰退的被动监测工具。
- 神经嵌入终点可用于神经保护试验的样本量估算,支持未来临床试验设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This 24-month longitudinal study involving isolated rapid eye movement sleep behavior disorder (iRBD), early-stage Parkinson's disease (PD), and matched healthy control subjects aimed to assess whether acoustic speech features from real-world smartphone calls provide passive progressive biomarkers in synucleinopathies. METHODS: Participants underwent clinical assessments at baseline, 1, and 2 years. Speech was continuously captured during phone calls via a standardized smartphone application, segmented, and analyzed for speech impairment severity end points and key acoustic features of monopitch, vowel articulation, voice quality, and articulation rate. We used linear mixed-effect modeling to estimate speech progression and calculated sample size requirements to demonstrate slowing of progression under anticipated treatment effects. RESULTS: Over 31,000 phone calls (>1,000 hours) were collected from 71 participants including those with iRBD, PD, and healthy controls. Compared with controls, both individuals with iRBD and PD showed significant declines in speech impairment severity end points based on spectral changes and artificial intelligence-based neural embeddings. The subjects with iRBD also exhibited declines in vowel articulation and articulation rate. For a 2-year neuroprotective trial aiming for 50% drug efficacy, the most efficient sample size estimate based on time-to-event analysis was 74 iRBD and 84 PD participants per arm using the neural embedding end point. INTERPRETATION: The phone call analysis requiring no patient effort or clinical supervision can detect speech decline in prodromal and early synucleinopathies, providing a potential paradigm shift for clinical trial design and neuroprotective intervention end points. ANN NEUROL 2026;99:935-948.
引用
- Šimek M, Tykalová T, Novotný M, et al. Speech Biomarkers From Smartphone Calls Track Progression in REM Sleep Behavior Disorder and Parkinson's Disease. Ann Neurol. 2025. PMID: 41467327. doi:10.1002/ana.78140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。